uniQure N.V. — Quarterly Financial Statements (NASDAQ:QURE) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Market Capitalization 914.61 M
Employee 209
Founded 1998
CEO Matt Kapusta
Website www.uniqure.com
Headquarter Netherlands
FIGI UNKNOWN
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

914.61 M Market capitalization

Price to earnings ratio

-13.36

Price to sales ratio

197.14

Dividends per share

—

Dividend yield %

—

uniQure N.V

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

News

uniQure: Shares Tumble On Fresh FDA Controversy - What Investors Should Know (NASDAQ:QURE)

uniQure earnings in focus as AMT-130 regulatory path looms

Stifel comments on uniQure shares after FDA commissioner remarks

Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug

Applied Materials, Broadcom among market cap stock movers on Thursday

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates

UniQure stock tumbles on FDA comments about gene therapy trial

uniQure stock initiated at Peerperform by Wolfe Research

uniQure investors face April 13 deadline for class action lawsuit

Diamond Hill International Strategy Q4 2025 Portfolio Review

uniqure investor lawsuit deadline set for April 13 following FDA setback

Uniqure stock rises after AMT-191 gene therapy shows promising Fabry results